ESTRO 2022 - Abstract Book

S214

Abstract book

ESTRO 2022

Conclusion Mean dose to the inferior section of the brainstem is strongly associated with dysphagia at 1 year following HN RT. The identified region is in proximity to swallowing centres in the medulla oblongata, providing a possible mechanistic explanation. Unexpectedly, no significant region was found close to the pharyngeal constrictor muscles or salivary glands, despite dose to these structures being predictive for dysphagia in previous studies. Mean, rather than max dose, was most predictive, possibly indicating a parallel organ effect or a serial effect in small substructures (masked by imperfect registration). Research is required to derive a dose constraint for RT planning.

OC-0256 Biomarker development from joint analyses of HNSCC xenografts and patients treated by PORT-C

A. Linge 1,2,3,4 , S. Patil 5,6 , K. Gurtner 6,1,7 , M. Grosser 8 , F. Lohaus 5,6,1,7 , V. Gudziol 9 , A. Nowak 10 , I. Tinhofer 11,12 , V. Budach 11,12 , M. Guberina 13,14 , M. Stuschke 15,14 , P. Balermpas 16,17 , C. Rödel 16,17 , H. Schäfer 18,19 , A. Grosu 18,19 , A. Abdollahi 20,21,22,23,24 , J. Debus 20,21,22,23,25 , C. Belka 26,27,28 , S. Pigorsch 26,29 , S.E. Combs 26,29,30 , S. Boeke 31,32 , D. Zips 31,32 , M. Baumann 33,6,1 , S. Löck 5,6,1,7 , M. Krause 34,6,1,7,35 1 Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; 2 German Cancer Research Center (DKFZ), Heidelberg, German Cancer Consortium (DKTK), partner site Dresden, Dresden, Germany; 3 OncoRay - Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Germany; 4 National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany , Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and Helmholtz Association / Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany; 5 German Cancer Research Center (DKFZ),Heidelberg, Germany, German Cancer Consortium (DKTK), partner site Dresden, Dresden, Germany; 6 OncoRay - Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden - Rossendorf, Dresden, Dresden, Germany; 7 National Center for Tumor Diseases (NCT), Partner Site Dresden, Germany: German Cancer Research Center (DKFZ), Heidelberg, Germany, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, and Helmholtz Association / Helmholtz-Zentrum Dresden - Rossendorf (HZDR), Dresden, Germany; 8 Institute of Pathology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; 9 Department of Otorhinolaryngology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; 10 Department of Oral and Maxillofacial Surgery, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; 11 German Cancer Research Center (DKFZ), Heidelberg, Germany, German Cancer Consortium (DKTK), partner site Berlin, Berlin, Germany; 12 Charité University Medicine Berlin, Department of Radiooncology and Radiotherapy, Berlin, Germany; 13 German Cancer Research Center (DKFZ), Heidelberg, Germany, , German Cancer Consortium (DKTK), partner site Essen, Essen, Germany; 14 Department of Radiotherapy, Medical Faculty, University of